Dr Reddy’s Labs unveils Doxycycline Capsules, 40 mg in US to treat inflammatory lesions of rosacea
Hyderabad: Dr Reddy’s Laboratories Ltd. has announced its launch of Doxycycline Capsules, 40 mg in the U.S. market, a therapeutic generic
equivalent of ORACEA (doxycycline, USP) Capsules, 40 mg approved by the U.S. Food and Drug
Administration (USFDA).
Doxycycline is a tetracycline-class drug indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. Inflammatory lesions, including papules and pustules, are common symptoms of rosacea. These lesions manifest as raised, red bumps (papules) and pus-filled bumps (pustules) on the skin, typically on the face. They are often accompanied by redness, swelling, and sensitivity in the affected areas.
Dr. Reddy’s Doxycycline Capsules, 40 mg, are supplied in bottle counts of 30. Each capsule contains: 26 mg immediate-release pellets and 14 mg delayed-release pellets equivalent to 40 mg of
anhydrous doxycycline, USP.
ORACEA is a trademark of Galderma Holdings, S.A.
Established in 1984, Dr Reddy’s Laboratories Ltd. is a global pharmaceutical company headquartered in Hyderabad, India. Dr Reddys offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr Reddys major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe.
